Holen Sie sich die Stockscreener-App
65.39
3.76%
2.37
Handel nachbörslich:
65.32
-0.07
-0.11%
Schlusskurs vom Vortag:
$63.02
Offen:
$64.06
24-Stunden-Volumen:
284.02K
Relative Volume:
0.56
Marktkapitalisierung:
$1.88B
Einnahmen:
$234.60M
Nettoeinkommen (Verlust:
$-13.23M
KGV:
-125.61
EPS:
-0.5206
Netto-Cashflow:
$19.61M
1W Leistung:
+1.04%
1M Leistung:
+18.65%
6M Leistung:
+196.69%
1J Leistung:
+254.61%
1-Tages-Spanne:
$64.00
$66.01
1-Wochen-Bereich:
$60.92
$66.01
52-Wochen-Spanne:
$15.40
$68.39
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
65.39 | 1.81B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Analysis Recap: Can AnaptysBio Inc grow without external fundingRecession Risk & Weekly High Return Stock Forecasts - baoquankhu1.vn
Investment Report: Can AnaptysBio Inc reach all time highs this yearLong Setup & Daily Price Action Insights - baoquankhu1.vn
RSI Check: Will AnaptysBio Inc benefit from geopolitical trends2026 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume – Should You Buy? - Defense World
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - MSN
Tranche Update on AnaptysBio, Inc.'s Equity Buyback Plan announced on March 24, 2025. - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Aug Levels: Does AnaptysBio Inc stock have upside surprise potential2026 Recap & Low Drawdown Investment Strategies - baoquankhu1.vn
ANAB Rating Boost: UBS Raises Price Target to $90 | ANAB Stock N - GuruFocus
UBS Group Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
UBS raises AnaptysBio stock price target to $90 on pipeline upside - Investing.com Australia
UBS raises AnaptysBio stock price target to $90 on pipeline upside By Investing.com - Investing.com South Africa
AnaptysBio, Inc. $ANAB Shares Purchased by Granahan Investment Management LLC - MarketBeat
AnaptysBio Hits New 12-Month High - National Today
How (ANAB) Movements Inform Risk Allocation Models - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighShould You Buy? - MarketBeat
AnaptysBio stock hits 52-week high at 66.73 USD By Investing.com - Investing.com Australia
Psoriasis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Can-Fite Biopha - Barchart
AnaptysBio stock hits 52-week high at 66.73 USD - Investing.com
Adaptive Biotechnologies (ADPT) Rises 5.8%: Can This Momentum Continue? - Bitget
First Light Asset Management Reduces Stake in AnaptysBio - National Today
First Light Asset Management LLC Sells 2,549,432 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - MSN
Aug Fed Impact: Can AnaptysBio Inc grow without external funding2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
AnaptysBio (ANAB): Wedbush Raises Price Target to $75 with Outpe - GuruFocus
Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
Wedbush Raises Price Target on AnaptysBio to $75 From $60, Keeps Outperform Rating - marketscreener.com
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline - MarketBeat
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighWhat's Next? - MarketBeat
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible - MarketBeat
Barclays Initiates Coverage of AnaptysBio (ANAB) with Overweight Recommendation - MSN
ANAB: Biopharma spin-off advances antibody pipeline as royalty business leverages Jemperli growth - TradingView
ANAB: Truist Securities Maintains Hold Rating, Raises Price Targ - GuruFocus
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc. - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio, Inc. Experiences Revision in Its Stock Evaluation Amid Market Trends - Markets Mojo
Truist raises AnaptysBio stock price target to $50 on Jemperli outlook - Investing.com Canada
Truist Adjusts Price Target on AnaptysBio to $50 From $36, Maintains Hold Rating - marketscreener.com
What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings? - MarketBeat
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress - Yahoo Finance
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - Sahm
Trading Systems Reacting to (ANAB) Volatility - Stock Traders Daily
AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Nigeria
HC Wainwright Weighs in on AnaptysBio FY2030 Earnings - MarketBeat
AnaptysBio, Inc. Hits New 52-Week High of $62.69, Up 156% - Markets Mojo
AnaptysBio Stock Soars 14.61%, Hits Intraday High of $62.69 - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $85.00 at Stifel Nicolaus - MarketBeat
Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus
AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com South Africa
AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):